NASDAQ:PTPI

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Petros Pharmaceuticals logo
$0.0021 0.00 (-8.70%)
As of 11/20/2026 11:22 AM Eastern

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Advanced

Key Stats

Today's Range
$0.0015
▼
$0.0021
50-Day Range
N/A
52-Week Range
$0.0015
▼
$0.0158
Volume
10,394 shs
Average Volume
117,799 shs
Market Capitalization
$65.44 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Petros Pharmaceuticals is a pharmaceutical company focused on treatments for men’s health conditions. Its work has included developing and commercializing prescription therapies and exploring ways to make certain treatments available directly to consumers.

The company’s best-known product is Stendra (avanafil), a prescription medication approved in the United States to treat erectile dysfunction. Petros has also pursued a potential prescription-to-over-the-counter transition for the treatment, which would involve regulatory review.

Petros has concentrated its business on men’s health and consumer access to medicines. Its product portfolio and commercial activities may change over time as the company pursues development, regulatory, and business opportunities.

AI Generated. May Contain Errors.

Receive PTPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTPI Stock News Headlines

Petros Pharmaceuticals Delays Annual 10-K Filing
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Petros Pharmaceuticals Inc (PTPI) - Investing.com
See More Headlines

PTPI Stock Analysis - Frequently Asked Questions

Petros Pharmaceuticals' stock was trading at $0.0071 at the beginning of 2026. Since then, PTPI stock has decreased by 70.4% and is now trading at $0.0021.

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($8.46) earnings per share (EPS) for the quarter.

Petros Pharmaceuticals shares reverse split on Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Advanced Micro Devices (AMD), AMC Entertainment (AMC), NIO (NIO), Biofrontera (BFRI), Biora Therapeutics (BIOR), Ensysce Biosciences (ENSC) and iSpecimen (ISPC).

Company Calendar

Today
11/21/2026
Next Earnings (Estimated)
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PTPI
CIK
1815903
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.16 million
Net Margins
N/A
Pretax Margin
-117.50%
Return on Equity
-78.22%
Return on Assets
-23.50%

Debt

Debt-to-Equity Ratio
1.58
Current Ratio
0.85
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$5.11 million
Price / Sales
0.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
31,160,000
Free Float
9,932,000
Market Cap
$65.44 thousand
Optionable
Not Optionable
Beta
2.04
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PTPI) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners